Astellas, Pfizer Extend Lipitor Marketing Agreement For Japan To 2021
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma and Pfizer have agreed to extend their licensing agreement for Japan marketing of cholesterol drug Lipitor (atorvastatin) for another five years.